<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Leifke, Eckhard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TAK-875 Reduces HbA1C in Patients with T2DM</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">TAK-875 is a selective G-protein-coupled receptor 40 (GPR40) agonist that is being developed as an adjunct therapy to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Results of a Phase 2 [NCT01007097] trial that has shown the glucose-lowering efficacy, safety, and tolerability of TAK-875 in a clinical setting are discussed.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>